Log in

NASDAQ:RDUSRadius Health Stock Price, Forecast & News

+0.39 (+3.36 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $12.01
50-Day Range
MA: $13.37
52-Week Range
Now: $12.01
Volume1.23 million shs
Average Volume740,082 shs
Market Capitalization$557.14 million
P/E RatioN/A
Dividend YieldN/A
Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; and Teijin Limited. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Read More
Radius Health logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.91 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:RDUS



Sales & Book Value

Annual Sales$173.32 million
Book Value($0.92) per share


Net Income$-132,990,000.00


Market Cap$557.14 million
Next Earnings Date8/10/2020 (Confirmed)
+0.39 (+3.36 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RDUS News and Ratings via Email

Sign-up to receive the latest news and ratings for RDUS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Radius Health (NASDAQ:RDUS) Frequently Asked Questions

How has Radius Health's stock been impacted by COVID-19 (Coronavirus)?

Radius Health's stock was trading at $16.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RDUS stock has decreased by 25.2% and is now trading at $12.01.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Radius Health?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Radius Health

When is Radius Health's next earnings date?

Radius Health is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Radius Health

How can I listen to Radius Health's earnings call?

Radius Health will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Radius Health's earnings last quarter?

Radius Health Inc (NASDAQ:RDUS) released its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.72) by $0.09. The biopharmaceutical company had revenue of $47.92 million for the quarter, compared to analyst estimates of $46.77 million.
View Radius Health's earnings history

What price target have analysts set for RDUS?

8 Wall Street analysts have issued 1 year target prices for Radius Health's stock. Their forecasts range from $18.00 to $40.00. On average, they anticipate Radius Health's stock price to reach $25.71 in the next year. This suggests a possible upside of 114.1% from the stock's current price.
View analysts' price targets for Radius Health

Has Radius Health been receiving favorable news coverage?

Headlines about RDUS stock have been trending very positive this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Radius Health earned a news sentiment score of 4.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future.
View the latest news about Radius Health

Who are some of Radius Health's key competitors?

What other stocks do shareholders of Radius Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), EXACT Sciences (EXAS), Cara Therapeutics (CARA), Amarin (AMRN), Opko Health (OPK), Portola Pharmaceuticals (PTLA), Netflix (NFLX), ACADIA Pharmaceuticals (ACAD) and Micron Technology (MU).

Who are Radius Health's key executives?

Radius Health's management team includes the following people:
  • Mr. Jesper Høiland, Pres, CEO & Director (Age 59)
  • Mr. Jose Carmona, CFO, Sr. VP & Treasurer (Age 47)
  • Mr. Brent Hatzis-Schoch Esq., J.D., Sr. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Brian Nicholas Harvey, Advisor (Age 58)
  • Dr. Stavros C. Manolagas, Co-Founder & Member of the Scientific Advisory Board

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

Who are Radius Health's major shareholders?

Radius Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Emerald Advisers LLC (1.93%), Rhenman & Partners Asset Management AB (0.72%), Russell Investments Group Ltd. (0.30%), MERIAN GLOBAL INVESTORS UK Ltd (0.28%), Swiss National Bank (0.22%) and Mackay Shields LLC (0.16%). Company insiders that own Radius Health stock include Anthony Rosenberg, Debasish Roychowdhury, Growth N V Biotech, Jessica Hopfield, Joseph Francis Kelly, Target N V Biotech and Willard H Dere.
View institutional ownership trends for Radius Health

Which institutional investors are selling Radius Health stock?

RDUS stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC.
View insider buying and selling activity for Radius Health

Which institutional investors are buying Radius Health stock?

RDUS stock was purchased by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Rhenman & Partners Asset Management AB, Rafferty Asset Management LLC, Swiss National Bank, Russell Investments Group Ltd., Virtus ETF Advisers LLC, Mackay Shields LLC, and ProShare Advisors LLC. Company insiders that have bought Radius Health stock in the last two years include Growth N V Biotech, Jessica Hopfield, Joseph Francis Kelly, and Target N V Biotech.
View insider buying and selling activity for Radius Health

How do I buy shares of Radius Health?

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Radius Health's stock price today?

One share of RDUS stock can currently be purchased for approximately $12.01.

How big of a company is Radius Health?

Radius Health has a market capitalization of $557.14 million and generates $173.32 million in revenue each year. The biopharmaceutical company earns $-132,990,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. Radius Health employs 398 workers across the globe.

What is Radius Health's official website?

The official website for Radius Health is www.radiuspharm.com.

How can I contact Radius Health?

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.